New initiative seeks to accelerate global collaborative research on COVID-19

NewsGuard 100/100 Score

During the COVID-19 pandemic, health care professionals and researchers have been confined mostly to using local and national datasets to study the impact of comorbidities, pre-existing medication use, demographics and various interventions on disease course.

Now, Purdue University is joining with other organizations for an initiative to accelerate global collaborative research on COVID-19 through access to high-quality, real-time multi-center patient datasets. The National Science Foundation has provided funding to develop the Records Evaluation for COVID-19 Emergency Research (RECovER) initiative.

Researchers are testing predictions of artificial intelligence drug discovery platforms from the lab of Gaurav Chopra, an assistant professor of analytical and physical chemistry in Purdue's College of Science, on patient datasets across a network of health care institutions.

They are using the technology to find trends and data connections to help better understand and treat COVID-19, with a special emphasis on the impact existing medications have on COVID-19.

This collaboration makes it possible to do decentralized electronic health record dataset searches from several medical institutions. Our approach allows a health care professional or researcher to identify patterns in patient responses to drugs, select or rank the predictions from our platform for drug repurposing and evaluate their responses over time. This will help with COVID-19 and other potential pandemics."

Gaurav Chopra, Assistant Professor, Analytical and Physical Chemistry, Purdue College of Science

Other institutions involved in the initiative include SUNY Buffalo, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine and Onai, a company specializing in blockchain/crypto technology.

"Onai is pleased to enable rapid secure research across COVID-19 medical records," said Galana Gebisa, a manager at Onai. "Applying Onai technology, data remains local and private within each participating institution. By querying across institutions, researchers can access a larger, more statistically significant dataset, to learn useful information earlier than they otherwise would."

Chopra's team published a paper in Drug Discovery Today on drug repurposing for pandemics.

"Our long-term goal is to not only repurpose drugs, but also design new ones in the context of their proteomic interaction environments in a faster, cheaper, safer, and better manner," said Ram Samudrala, the other senior co-author on this study.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 booster enhances virus neutralizing antibodies in breast milk, new study reveals